By Dana Mattioli and Jonathan D. Rockoff 

Sanofi SA is nearing a deal to buy hemophilia drugmaker Bioverativ Inc. for more than $11.5 billion as the French drugmaker looks set to clinch a big deal while it braces for generic competition for its top-selling product.

A deal, which could be announced as soon as Monday, would value the former Biogen Inc. unit at $105 a share, according to people familiar with the matter. The price would represent a 63% premium to where Bioverativ closed trading Friday. It is possible the talks could fall apart before a deal is reached.

(More to come)

 

(END) Dow Jones Newswires

January 21, 2018 20:34 ET (01:34 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.
Bioverativ Inc. (NASDAQ:BIVV)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Bioverativ Inc. Charts.
Bioverativ Inc. (NASDAQ:BIVV)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Bioverativ Inc. Charts.